389 results about "Bicarbonate" patented technology

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory disease using the pharmaceutical composition disclosed herein.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are dosage forms comprising a combination of: 1) an active pharmaceutical ingredient (API), 2) a cyclodextrin, and 3) a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.

This application relates to the field of ceramsite, and specifically discloses a process method for producing coal gangue ceramsite by microwave drying, which includes the following steps: Coal gangue pretreatment: Granulate coal gangue powder and bicarbonate under the action of a wetting agent to form green coal gangue balls, and dry the green coal gangue balls with microwave; 90 - 100 parts of coal gangue powder, 1 - 4 parts of bicarbonate, 3 - 8 parts of wetting agent; The wetting agent includes raw materials in the following weight parts: 1 - 3 parts of polyvinyl alcohol, 1.5 - 4 parts of sodium carboxymethylcellulose, 0.5 - 1 part of surfactant; Coal gangue ceramsite preparation: After pyrolysis, decarbonization, sintering, and cooling of the dried green coal gangue balls, ceramsite is formed; Pyrolysis includes: Gradient oxygen-controlled pyrolysis of the dried green coal gangue balls, the pyrolysis temperature is 250 - 450 °C, and at the same time, air flow is intermittently introduced to impact the material layer. This method can significantly reduce the bursting rate of ceramsite, the surface of the ceramsite has no cracks, the strength is high, and the product quality is excellent.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

A process for the production of carbon monoxide is described. The process involves the electrochemical desorption of carbon dioxide and oxygen from a solution containing a metal bicarbonate and the formation of carbon monoxide from the carbon dioxide. The carbon monoxide produced can be used in a process for the formation of syngas.

The invention belongs to the field of water pollution treatment, and particularly relates to a method for degrading chlorophenol organic pollutants in water by activating persulfate with a cobalt-cerium dioxide monatomic catalyst in the presence of bicarbonate radicals. According to the invention, cerium nitrate hexahydrate is calcined in a muffle furnace to obtain cerium dioxide. A catalyst precursor is prepared by a traditional isovolumetric impregnation method. The prepared catalyst precursor is annealed at different temperatures to obtain a series of catalysts, the catalytic performance of Co1-CeO2-700 is optimal, and the Co1-CeO2-700 has more excellent catalytic performance in the presence of bicarbonate radicals. The preparation method provided by the invention has the advantages of simple steps, convenience in operation, quick effect of treating chlorophenol, high product yield and low cost, and has good economic value and social benefit. The prepared monatomic catalyst has the advantages of being high in atom utilization rate, good in stability, excellent in catalytic effect and the like, and is expected to become a key technology for solving actual water environment organic pollution.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

A method for regenerating an amine-containing sorbent useful in the capture of carbon dioxide (CO2), by contacting a CO2 complex of the amine-containing sorbent in solution with a metal oxide material while the solution is at a temperature within a range of 60-130° C. to result in release of CO2 and regeneration of the amine-containing sorbent, wherein the CO2 in the CO2 complex is in the form of a carbamate or bicarbonate moiety attached to the amine-containing sorbent. The method may also include re-using the regenerated sorbent to capture carbon dioxide. The sorbent may be, for example, an amino acid (e.g., glycine), alkylamine, alkanolamine, or amine biphasic solvent. The metal oxide material may more particularly be selected from the group consisting of TiO2, TiO(OH)2, MoO3, V2O5, Cr2O3, WO3, Ag2O, Nb2O5, NiO, CuO, MnO2, ZrO2, Fe2O3, Fe3O4, ZnO, and combinations thereof.

The invention provides a device for extracting cesium from lepidolite and preparing cesium formate by a preparation system of cesium formate, which comprises: an extraction section, which comprises a plurality of first high-speed centrifugal extractors connected in series, and a first extraction inlet of the first high-speed centrifugal extractor of the last stage is introduced with a liquid to be extracted; the to-be-extracted liquid is leached frozen clear liquid of lepidolite, and the frozen clear liquid is alkaline and comprises cesium, rubidium, sodium, potassium and lithium ions; the t-BAMBP is diluted by adopting ESCAID 110 as an extraction agent, the concentration of the extraction agent is 0.4-0.6 mol / L of t-BAMBP, and the O / A ratio in the extraction section is 1: (1.8-2.0); the washing section comprises a plurality of second high-speed centrifugal extractors which are connected in series; the back extraction section comprises a third high-speed centrifugal extractor, and cesium bicarbonate back extraction post-liquid flows out of a first back extraction outlet of the third high-speed centrifugal extractor; the oil removal section is used for removing oil from the cesium bicarbonate back-extraction post-liquid; and the evaporation and concentration section is used for introducing formic acid for neutralization reaction to form a cesium formate solution after oil removal, and then evaporating and concentrating the cesium formate solution to obtain the final cesium formate solution.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a ketoazine-based polymer, an anion exchange membrane and a preparation method and application of the ketoazine-based polymer and the anion exchange membrane. A first linking group and a second linking group are mixed and then mixed with an aryl monomer A in an aprotic solvent of halogen atoms; slowly adding a super acid mixture; performing polymerization reaction in an environment of-5 to 3 DEG C to obtain a reaction solution; pouring the reaction liquid into a first mixed solvent to obtain PAAz; carrying out primary quaternization reaction on PAAz through carbonate, bicarbonate or hydroxide salt of alkali metal, and adding an organic base catalyst to assist the primary quaternization reaction; in the first quaternization reaction, a quaternization reagent is added; and pouring into a second mixed solvent, and precipitating to obtain purified PAAz. Under the condition of super acid catalysis, two or more alicyclic amine derivatives containing ketone groups react with one or more aromatic fused rings to generate a polymer containing secondary or tertiary amine. And carrying out quaternization treatment to finally form the cationic polymer.

Methods and apparatuses for converting carbon dioxide to useful compounds are disclosed. The method involves reducing bicarbonate solution in an electrolyzer. Bicarbonate solution is supplied to the cathode. The direct reduction of bicarbonate at the cathode may be coupled with an oxidation reaction at the anode. The oxidation reaction may provide a source of protons (H+) to cathode for the reduction of bicarbonate. The oxidation reaction may be a hydrogen oxidation reaction (HOR). Hydrogen gas (H2) may be supplied to the anode. In some embodiments, a source of gas may be supplied to the bicarbonate solution to form a pressurized solution before supplying the solution to the cathode.

A process for producing methane is specified. According to one embodiment, the process comprises a first reaction stage (S1) comprising calcining a metal bicarbonate in a first reaction volume (1) to form carbon dioxide and reacting the carbon dioxide with hydrogen gas in a second reaction volume (2) to form gaseous products (3), wherein one of the gaseous products (3) is methane and wherein thermal energy released during the reaction of the carbon dioxide is used to calcine the metal bicarbonate.

A system and method for acid gas removal are provided. An exemplary system includes a contactor that includes an inlet for an aqueous carbonate stream proximate to a top of the contactor, wherein the aqueous carbonate stream includes a catalyst. The contactor also includes an inlet for a gas stream proximate to a bottom of the contactor, wherein the gas stream includes an acid gas. Further, the contactor includes an outlet for an aqueous bicarbonate-carbonate stream proximate to the bottom of the contactor, and an outlet for a sweetened gas stream proximate to the top of the contactor. The acid gas removal system also includes a nanofilter. The aqueous bicarbonate-carbonate stream is introduced at an inlet to the nanofilter, and a permeate stream from the nanofilter is fed to a flash column. The nanofilter also provides a retentate stream including carbonate ions, wherein the retentate stream is fed to the contactor.

The application discloses a preparation method and purification process of copper hydroxide, a certain amount of anhydrous copper sulfate is accurately weighed, and a certain volume of deionized water is added to prepare a solution with a certain concentration, a copper ammonia solution is prepared: slurry is prepared from circuit board sludge, screening is performed, ammonium bicarbonate or ammonium carbonate is added for reaction, and a copper ammonia solution containing carbonate or bicarbonate is obtained through purification; in addition, high-purity copper powder is added into concentrated ammonia water, concentrated hydrogen peroxide solution is slowly dropped into the concentrated ammonia water, and the dropping is continued until no large amount of bubbles is generated in the solution, and the solution is filtered to obtain a clear indigo blue solution. The production process adds the step of adding a stabilizer and stirring, guarantees the stable state of the copper hydroxide crystal, and enables the copper hydroxide crystal to remain unchanged into copper oxide for one year in an environment with a temperature as high as 60 degrees.

The present disclosure provides an electrocatalytic reactor and method of electrochemical conversion of carbon dioxide (CO2) into value-added products (VAPs) The electrocatalytic reactor includes Stainless Steel (SS), or Copper (Cu) or Copper alloy (Cu-alloy) electrodes, wherein one or more anode is an SS electrode, wherein the electrodes act as electrocatalyst, and acidified deionised water (H3O+) is used as electrolyte for generation of H2 gas through bulk electrocatalysis, wherein a catalyst initiator that includes 80% by weight of metal carbonates or bicarbonates of Mg or Na with 20% by weight of MgO is used to facilitate the reaction of the short-lived cation radical intermediates formed by C- C coupling reactions on the cathode surface leading to hydrolysis and VAPs formation with high specificity and selectivity.

To improve the adhesion of the coating film to the resin and the resistance of the coating films to blocking each other. [Solution] The polyurethane aqueous dispersion according to the embodiment comprises a polyurethane resin (A) containing a polyester polyol as a constituent component dispersed in an aqueous dispersion medium, and includes a carbodiimide group-containing compound (B) and a salt (C) of an acid and an alkali metal. The polyurethane resin (A) has carboxyl groups, and the salt (C) is at least one selected from the group consisting of bicarbonates, carbonates, monocarboxylates, dicarboxylates, tricarboxylates, and phosphates, and the salt (C) exists in an ionized state in the aqueous dispersion medium.